MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keac097

Медицинская библиотека · Rheumatology (Oxford, England) · 2022

Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review.

Herrero-Morant Alba, Martín-Varillas José Luis, Castañeda Santos, Maíz Olga, Sánchez Julio, Ortego Norberto, Raya Enrique, Prior-Español Águeda, Moriano Clara, Melero-González Rafael B, Graña-Gil Jenaro, Urruticoechea-Arana Ana, Ramos-Calvo Ángel, Loredo-Martínez Marta, Salgado-Pérez Eva, Sivera Francisca, Torre Ignacio, Narváez Javier, Andreu José Luis, Martínez-González Olga, Torre Ricardo Gómez-de la, Fernández-Aguado Sabela, Romero-Yuste Susana, González-Mazón Íñigo, Álvarez-Reguera Carmen, Hernández José Luis, González-Gay Miguel Ángel, Blanco Ricardo, Neurobehçet Spanish Collaborative Group

ОбзорСтатьяПеревод в очереди

Аннотация

OBJECTIVES

To assess efficacy and safety of biologic therapy (BT) in neurobehçet's disease (NBD) refractory to glucocorticoids and at least one conventional immunosuppressive drug.

METHODS

Open-label, national, multicentre study. NBD diagnosis was based on the International Consensus Recommendation criteria. Outcome variables were efficacy and safety. Main efficacy outcome was clinical remission. Other outcome variables analysed were glucocorticoid-sparing effect and improvement in laboratory parameters.

RESULTS

We studied 41 patients [21 women; age 40.6 (10.8) years]. Neurological damage was parenchymal (n = 33, 80.5%) and non-parenchymal (n = 17, 41.5%). First BTs used were infliximab (n = 19), adalimumab (n = 14), golimumab (n = 3), tocilizumab (n = 3) and etanercept (n = 2). After 6 months of BT, neurological remission was complete (n = 23, 56.1%), partial (n = 15, 37.6%) and no response (n = 3, 7.3%). In addition, median (IQR) dose of oral prednisone decreased from 60 (30-60) mg/day at the initial visit to 5 (3.8-10) mg/day after 6 months (P < 0.001). It was also the case for mean erythrocyte sedimentation rate [31.5 (25.6)-15.3 (11.9) mm/1st h, P = 0.011] and median (IQR) C-reactive protein [1.4 (0.2-12.8) to 0.3 (0.1-3) mg/dl, P = 0.001]. After a mean follow-up of 57.5 months, partial or complete neurological remission persisted in 37 patients (90.2%). BT was switched in 22 cases (53.6%) due to inefficacy (n = 16) or adverse events (AEs) (n = 6) and discontinued due to complete prolonged remission (n = 3) or severe AE (n = 1). Serious AEs were observed in two patients under infliximab treatment.

CONCLUSIONS

BT appears to be effective and relatively safe in refractory NBD.

Для цитирования: Herrero-Morant Alba, Martín-Varillas José Luis, Castañeda Santos, Maíz Olga, Sánchez Julio, Ortego Norberto, Raya Enrique, Prior-Español Águeda, Moriano Clara, Melero-González Rafael B, Graña-Gil Jenaro, Urruticoechea-Arana Ana, Ramos-Calvo Ángel, Loredo-Martínez Marta, Salgado-Pérez Eva, Sivera Francisca, Torre Ignacio, Narváez Javier, Andreu José Luis, Martínez-González Olga, Torre Ricardo Gómez-de la, Fernández-Aguado Sabela, Romero-Yuste Susana, González-Mazón Íñigo, Álvarez-Reguera Carmen, Hernández José Luis, González-Gay Miguel Ángel, Blanco Ricardo, Neurobehçet Spanish Collaborative Group. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review.. Rheumatology (Oxford, England). 2022. DOI: 10.1093/rheumatology/keac097.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.